Search Results

There are 10225 results for: content related to: Epidermal growth factor receptor activation and inhibition in 3 D in vitro models of normal skin and human cutaneous squamous cell carcinoma

  1. You have full text access to this Open Access content
    JAK2-related pathway induces acquired erlotinib resistance in lung cancer cells harboring an epidermal growth factor receptor-activating mutation

    Cancer Science

    Volume 103, Issue 10, October 2012, Pages: 1795–1802, Daijiro Harada, Nagio Takigawa, Nobuaki Ochi, Takashi Ninomiya, Masayuki Yasugi, Toshio Kubo, Hiromasa Takeda, Eiki Ichihara, Kadoaki Ohashi, Saburo Takata, Mitsune Tanimoto and Katsuyuki Kiura

    Version of Record online : 23 JUL 2012, DOI: 10.1111/j.1349-7006.2012.02363.x

  2. You have full text access to this Open Access content
    Substrate-dependent bidirectional modulation of P-glycoprotein-mediated drug resistance by erlotinib

    Cancer Science

    Volume 100, Issue 9, September 2009, Pages: 1701–1707, Kohji Noguchi, Haruka Kawahara, Airi Kaji, Kazuhiro Katayama, Junko Mitsuhashi and Yoshikazu Sugimoto

    Version of Record online : 12 MAY 2009, DOI: 10.1111/j.1349-7006.2009.01213.x

  3. Synergistic effect of targeting the epidermal growth factor receptor and hyaluronan synthesis in oesophageal squamous cell carcinoma cells

    British Journal of Pharmacology

    Volume 172, Issue 18, September 2015, Pages: 4560–4574, I Kretschmer, T Freudenberger, S Twarock and J W Fischer

    Version of Record online : 30 JUL 2015, DOI: 10.1111/bph.13240

  4. Shikonin and its derivatives inhibit the epidermal growth factor receptor signaling and synergistically kill glioblastoma cells in combination with erlotinib

    International Journal of Cancer

    Volume 137, Issue 6, 15 September 2015, Pages: 1446–1456, Qiaoli Zhao, Nadine Kretschmer, Rudolf Bauer and Thomas Efferth

    Version of Record online : 6 MAR 2015, DOI: 10.1002/ijc.29483

  5. You have full text access to this Open Access content
    Enhanced antitumor activity of erlotinib in combination with the Hsp90 inhibitor CH5164840 against non-small-cell lung cancer

    Cancer Science

    Volume 104, Issue 10, October 2013, Pages: 1346–1352, Naomi Ono, Toshikazu Yamazaki, Toshiyuki Tsukaguchi, Toshihiko Fujii, Kiyoaki Sakata, Atsushi Suda, Takuo Tsukuda, Toshiyuki Mio, Nobuya Ishii, Osamu Kondoh and Yuko Aoki

    Version of Record online : 20 AUG 2013, DOI: 10.1111/cas.12237

  6. Identifying novel targets of oncogenic EGF receptor signaling in lung cancer through global phosphoproteomics

    PROTEOMICS

    Volume 15, Issue 2-3, January 2015, Pages: 340–355, Xu Zhang, Natalya Belkina, Harrys Kishore Charles Jacob, Tapan Maity, Romi Biswas, Abhilash Venugopalan, Patrick G. Shaw, Min-Sik Kim, Raghothama Chaerkady, Akhilesh Pandey and Udayan Guha

    Version of Record online : 15 JAN 2015, DOI: 10.1002/pmic.201400315

  7. You have full text access to this OnlineOpen article
    Enhanced anti-angiogenic effect of E7820 in combination with erlotinib in epidermal growth factor receptor–tyrosine kinase inhibitor-resistant non-small-cell lung cancer xenograft models

    Cancer Science

    Volume 105, Issue 8, August 2014, Pages: 1023–1031, Ken Ito, Taro Semba, Toshimitsu Uenaka, Toshiaki Wakabayashi, Makoto Asada and Yasuhiro Funahashi

    Version of Record online : 27 AUG 2014, DOI: 10.1111/cas.12450

  8. You have free access to this content
    Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma

    Hepatology

    Volume 59, Issue 4, April 2014, Pages: 1577–1590, Bryan C. Fuchs, Yujin Hoshida, Tsutomu Fujii, Lan Wei, Suguru Yamada, Gregory Y. Lauwers, Christopher M. McGinn, Danielle K. DePeralta, Xintong Chen, Toshihiko Kuroda, Michael Lanuti, Anthony D. Schmitt, Supriya Gupta, Andrew Crenshaw, Robert Onofrio, Bradley Taylor, Wendy Winckler, Nabeel Bardeesy, Peter Caravan, Todd R. Golub and Kenneth K. Tanabe

    Version of Record online : 28 FEB 2014, DOI: 10.1002/hep.26898

  9. Effect of erlotinib on epidermal growth factor receptor and downstream signaling in oral cavity squamous cell carcinoma

    Head & Neck

    Volume 35, Issue 9, September 2013, Pages: 1323–1330, Christina I. Tsien, Mukesh K. Nyati, Aarif Ahsan, Susmita G. Ramanand, Douglas B. Chepeha, Francis P. Worden, Joseph I. Helman, Nisha D'Silva, Carol R. Bradford, Gregory T. Wolf, Theodore S. Lawrence and Avraham Eisbruch

    Version of Record online : 21 AUG 2012, DOI: 10.1002/hed.23128

  10. Gene expression profiling on pre- and post-erlotinib tumors from patients with head and neck squamous cell carcinoma

    Head & Neck

    Volume 35, Issue 6, June 2013, Pages: 809–818, Fabienne Thomas, Paul Delmar, Sébastien Vergez, Philippe Rochaix, Isabelle Hennebelle, Patricia McLoughlin, Adil Benlyazid, Jérôme Sarini and Jean–Pierre Delord

    Version of Record online : 13 JUL 2012, DOI: 10.1002/hed.23036

  11. Coadministration of Erlotinib and Curcumin Augmentatively Reduces Cell Viability in Lung Cancer Cells

    Phytotherapy Research

    Volume 28, Issue 5, May 2014, Pages: 728–735, Yoshikane Yamauchi, Yotaro Izumi, Jun Yamamoto and Hiroaki Nomori

    Version of Record online : 13 AUG 2013, DOI: 10.1002/ptr.5056

  12. Population pharmacokinetics of erlotinib in Japanese patients with advanced non-small cell lung cancer

    Journal of Clinical Pharmacy and Therapeutics

    Volume 40, Issue 2, April 2015, Pages: 232–239, Y. Emoto-Yamamoto, S. Iida, T. Kawanishi and M. Fukuoka

    Version of Record online : 17 NOV 2014, DOI: 10.1111/jcpt.12232

  13. You have full text access to this Open Access content
    Salvage treatment with erlotinib after gefitinib failure in advanced non-small-cell lung cancer patients with poor performance status: A matched-pair case–control study

    Thoracic Cancer

    Volume 3, Issue 1, February 2012, Pages: 27–33, Daxian Luo, Meijuan Huang, Xinxing Zhang, Min Yu, Bingwen Zou, Yanying Li, Jianlin Long, Jin Wang, Feng Peng, Yong Xu, Lu Li, Li Ren, Mei Hou and You Lu

    Version of Record online : 5 FEB 2012, DOI: 10.1111/j.1759-7714.2011.00087.x

  14. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer

    Intervention Review

    The Cochrane Library

    Janette Greenhalgh, Kerry Dwan, Angela Boland, Victoria Bates, Fabio Vecchio, Yenal Dundar, Pooja Jain and John A Green

    Published Online : 25 MAY 2016, DOI: 10.1002/14651858.CD010383.pub2

  15. You have full text access to this OnlineOpen article
    Final safety and efficacy of erlotinib in the phase 4 POLARSTAR surveillance study of 10 708 Japanese patients with non-small-cell lung cancer

    Cancer Science

    Volume 105, Issue 12, December 2014, Pages: 1584–1590, Akihiko Gemma, Shoji Kudoh, Masahiko Ando, Yuichiro Ohe, Kazuhiko Nakagawa, Takeshi Johkoh, Naoya Yamazaki, Hiroaki Arakawa, Yoshikazu Inoue, Masahito Ebina, Masahiko Kusumoto, Kazuyoshi Kuwano, Fumikazu Sakai, Hiroyuki Taniguchi, Yuh Fukuda, Akihiro Seki, Tadashi Ishii and Masahiro Fukuoka

    Version of Record online : 15 DEC 2014, DOI: 10.1111/cas.12550

  16. Evaluation of the Absolute Oral Bioavailability and Bioequivalence of Erlotinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in a Randomized, Crossover Study in Healthy Subjects

    The Journal of Clinical Pharmacology

    Volume 46, Issue 3, March 2006, Pages: 282–290, Dr Paul Frohna, Dr Jianfeng Lu, Dr Steve Eppler, Dr Marta Hamilton, Ms Julie Wolf, Dr Ashok Rakhit, Dr Jie Ling, Dr Saraswati R. Kenkare-Mitra and Dr Bert L. Lum

    Version of Record online : 8 MAR 2013, DOI: 10.1177/0091270005284193

  17. Impact of nutritional status on the pharmacokinetics of erlotinib in rats

    Biopharmaceutics & Drug Disposition

    Volume 36, Issue 6, September 2015, Pages: 373–384, A. Pérez-Pitarch, A. Nácher, V. Merino, A. Catalán-Latorre, N.V. Jiménez-Torres and M. Merino-Sanjuán

    Version of Record online : 16 APR 2015, DOI: 10.1002/bdd.1948

  18. You have free access to this content
    Synergistic inhibition of head and neck tumor growth by green tea (−)-epigallocatechin-3-gallate and EGFR tyrosine kinase inhibitor

    International Journal of Cancer

    Volume 123, Issue 5, 1 September 2008, Pages: 1005–1014, Xin Zhang, Hongzheng Zhang, Mourad Tighiouart, John E. Lee, Hyung J. Shin, Fadlo R. Khuri, Chung S. Yang, Zhuo (Georgia) Chen and Dong M. Shin

    Version of Record online : 10 JUN 2008, DOI: 10.1002/ijc.23585

  19. Delay of treatment change after objective progression on first-line erlotinib in epidermal growth factor receptor-mutant lung cancer

    Cancer

    Volume 121, Issue 15, August 1, 2015, Pages: 2570–2577, Peter C. Lo, Suzanne E. Dahlberg, Mizuki Nishino, Bruce E. Johnson, Lecia V. Sequist, David M. Jackman, Pasi A. Jänne and Geoffrey R. Oxnard

    Version of Record online : 15 APR 2015, DOI: 10.1002/cncr.29397

  20. ERLOTINIB ACTIVATES MITOCHONDRIAL DEATH PATHWAYS RELATED TO THE PRODUCTION OF REACTIVE OXYGEN SPECIES IN THE HUMAN NON-SMALL CELL LUNG CANCER CELL LINE A549

    Clinical and Experimental Pharmacology and Physiology

    Volume 36, Issue 5-6, May/June 2009, Pages: 487–494, Xia Qian, Jing Li, Jianhua Ding, Zhiyuan Wang, Wenjing Zhang and Gang Hu

    Version of Record online : 8 OCT 2008, DOI: 10.1111/j.1440-1681.2008.05091.x